2. Search Result
Search Result
Pathways Recommended: NF-κB
Results for "

NF-

" in MedChemExpress (MCE) Product Catalog:

1297

Inhibitors & Agonists

9

Screening Libraries

6

Fluorescent Dye

21

Biochemical Assay Reagents

50

Peptides

15

Inhibitory Antibodies

597

Natural
Products

37

Recombinant Proteins

70

Isotope-Labeled Compounds

80

Antibodies

2

Click Chemistry

15

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134477
    NF-κΒ activator 2
    4 Publications Verification

    		 NF-κB Neurological Disease
    NF-κΒ activator 2 is a potent and orally active NF- B activator, with an EC50 of 1.58 μM. NF-κΒ activator 2 induces SOD2 through increasing NF- B expression and activation. NF-κΒ activator 2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
    NF-κΒ activator 2
  • HY-161719
    NF764

    		β-catenin Cancer
    NF764 is a potent β-catenin (CTNNB1) degrader. NF764 reduces CTNNB1 protein levels in a proteasome-dependent manner. NF764 can be used in the study of cancer .
    NF764
  • HY-155998
    NF-κB-IN-11

    		NF-κB Inflammation/Immunology
    NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .
    NF-κB-IN-11
  • HY-138537
    NF-κB-IN-1
    3 Publications Verification

    		 IKK Cancer
    NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .
    NF-κB-IN-1
  • HY-167704
    NF023

    		Apoptosis Cancer
    NF023 is a compound that inhibits X-BIR1/TAB1 assembly activity. NF023 can affect cell survival signaling pathways by interfering with XIAP-mediated NF-κB activation. NF023 also shows potential as a selective P2X1 adenylate receptor antagonist. This compound has the potential to synergize with existing pro-apoptotic drugs and play an important role in cancer suppression .
    NF023
  • HY-126026
    NF-κB-IN-17

    		NF-κB Inflammation/Immunology
    NF-κB-IN-17 (Zinc5) is a NF-κB inhibitor. NF-κB-IN-17 inhibits TNF-α-induced NF-κB DNA binding activity in C2C12 cells .
    NF-κB-IN-17
  • HY-108659
    NF340

    		P2Y Receptor Inflammation/Immunology
    NF340 is a potent and selective P2Y11 receptor antagonist. NF340 inhibits the activity of P2Y11R by completely combining with ATP-binding amino acid residues. NF340 ameliorates inflammation in human fibroblast-like synoviocytes and can be used for rheumatoid arthritis research .
    NF340
  • HY-149838
    NF-κB-IN-9

    		NF-κB Cancer
    NF-κB-IN-9 is a nuclear factor kappa B (NF-κB) targeting sonosensitizer (λex/λem=489/628 nm). NF-κB-IN-9 exhibits strong inhibition on NF-κB signaling due to its two resveratrol units in one molecule. NF-κB-IN-9 has anti-tumor activity and shows remarkable sonocytotoxicity against cancer cells. NF-κB-IN-9 has biosafety in eenograft mice model.
    NF-κB-IN-9
  • HY-144744
    NF-κB-IN-3

    		NF-κB Cancer
    NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .
    NF-κB-IN-3
  • HY-170659
    NF-κB-IN-18

    		NF-κB Inflammation/Immunology
    NF-κB-IN-18 (Compound 5k) is an orally active NF-κB inhibitor. NF-κB-IN-18 inhibits phosphorylation of p65. NF-κB-IN-18 exhibits potent anti-inflammatory activity in Xylene-induced ear edema mice .
    NF-κB-IN-18
  • HY-144765
    NF-κB-IN-4
    1 Publications Verification

    		 NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
    NF-κB-IN-4
  • HY-108661
    NF546

    		P2Y Receptor Inflammation/Immunology
    NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells .
    NF546
  • HY-108661A
    NF546 hydrate

    		P2Y Receptor Inflammation/Immunology
    NF546 (hydrate) is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 (hydrate) stimulates release of interleukin-8 from human monocyte-derived dendritic cells .
    NF546 hydrate
  • HY-149580
    NF-κB-IN-12

    		NF-κB Inflammation/Immunology
    NF-κB-IN-12 (compound 3h) is a potent NF-κB inhibitor, with an IC50 of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research .
    NF-κB-IN-12
  • HY-149351
    NF-κB-IN-10

    		NF-κB Cardiovascular Disease
    NF-κB-IN-10 (compound E1) is an NF-κB inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating Nrf2/NF-κB signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases .
    NF-κB-IN-10
  • HY-N12283
    NF-κB-IN-13

    		NF-κB Inflammation/Immunology
    NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced NF-κB activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .
    NF-κB-IN-13
  • HY-122382
    Levofuraltadone

    NF-602

    		 Parasite Bacterial Infection
    Levofuraltadone (NF-602) is an antibacterial and antiparasitic agent. Levofuraltadone has anti-trypanosomiasis activity and can be used in the study of human african trypanosomiasis as well as bacterial infections .
    Levofuraltadone
  • HY-149248
    NF-κB-IN-8

    		NF-κB Inflammation/Immunology
    NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI) .
    NF-κB-IN-8
  • HY-142958
    NF-κB-IN-2

    		NF-κB Neurological Disease
    NF-κB-IN-2 inhibits TNF-α-induced canonical NF-κB signaling in PC-3 cells.
    NF-κB-IN-2
  • HY-130246
    NF-56-EJ40
    5+ Cited Publications

    		 Succinate Receptor 1 Inflammation/Immunology
    NF-56-EJ40 is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
    NF-56-EJ40
  • HY-130246A
    NF-56-EJ40 hydrochloride

    		Succinate Receptor 1 Inflammation/Immunology
    NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM .
    NF-56-EJ40 hydrochloride
  • HY-172201
    NF-κB-IN-19

    		NF-κB Reactive Oxygen Species (ROS) Autophagy Apoptosis HIF/HIF Prolyl-Hydroxylase Akt STAT PI3K Inflammation/Immunology Cancer
    NF-κB-IN-19 (Compound 8) is an NF-κB inhibitor. NF-κB-IN-19 effectively induces DNA damage, promotes the generation of ROS, and induces autophagy and apoptosis through the NF-κB signaling pathway in tumor cells. In addition, NF-κB-IN-19 can inhibit the levels of VEGF and HIF-1α, and exert antiproliferative activity in tumor cells through the PI3K/AKT and STAT-3 pathways. NF-κB-IN-19 can effectively overcome cisplatin resistance and has anti-tumor activity .
    NF-κB-IN-19
  • HY-130284
    NF864

    		P2X Receptor Cardiovascular Disease
    NF864 is a selectivelyP2X1 receptorinhibitor in human platelets .
    NF864
  • HY-162316
    NF-κB-IN-15

    		NF-κB Inflammation/Immunology
    NF-κB-IN-15 (compound 14r) is a potent NF-κB inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) .
    NF-κB-IN-15
  • HY-D0976
    NF279

    		P2X Receptor HIV Infection
    NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC50 of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC50=1.62 μM), P2X4 (IC50>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env .
    NF279
  • HY-162004
    NF-κB-IN-14

    		NF-κB Toll-like Receptor (TLR) Inflammation/Immunology
    NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC50: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .
    NF-κB-IN-14
  • HY-147972
    NF-κB/MAPK-IN-1

    		NF-κB p38 MAPK NO Synthase COX Inflammation/Immunology
    NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of NF-κB and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC50 of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .
    NF-κB/MAPK-IN-1
  • HY-168482
    NF-κB/MAPK-IN-2

    		NF-κB p38 MAPK Cancer
    NF-κB/MAPK-IN-2 (compound 14) is a potent NF-κB and MAPK Inhibitor. NF-κB/MAPK-IN-2 decreases the protein expression of p-p65, p-IκB, p-p38, p-JNK, and p-ERK. NF-κB/MAPK-IN-2 reduces the LPS-induced release of TNF-α and IL-6. NF-κB/MAPK-IN-2 inhibits nuclear translocation of p65 and c-Fos. NF-κB/MAPK-IN-2 has the potential for the research of sepsis .
    NF-κB/MAPK-IN-2
  • HY-108671
    NF110

    		P2X Receptor Neurological Disease
    NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons .
    NF110
  • HY-158156
    NF-κB-IN-16

    		NF-κB Apoptosis Cancer
    NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .
    NF-κB-IN-16
  • HY-147682
    NF-κB-IN-5

    		NF-κB Apoptosis Cancer
    NF-κB-IN-5 (compound 4d) is an orally active and potent NF-κB inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC50 values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .
    NF-κB-IN-5
  • HY-147770
    NF-κB-IN-6

    		NF-κB Inflammation/Immunology
    NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent through the mechanism of decreasing the protein expressions of iNOS and COX-2 by suppressing NF-κB signaling pathway. NF-κB-IN-6 inhibits NO production in LPS-induced RAW264.7 cells with an IC50 of 23.1 μM .
    NF-κB-IN-6
  • HY-112461
    NF449

    		P2X Receptor Cardiovascular Disease
    NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449
  • HY-174138
    NF-κB degrader 1

    		NF-κB Inflammation/Immunology
    NF-κB degrader 1 (Compound MD-1) is a NF-κB1 p105 subunit degrader. NF-κB degrader 1 shows anti-inflammatory activity (IC50 for inhibiting TNF-α is 2.02 μM, and for inhibiting NO is 5.40 μM). NF-κB degrader 1 induces p105 degradation dependent on the Cullin-RING ligase (CRL) SCFBTCP, suppressing NF-κB transcriptional activity. NF-κB degrader 1 is promising for research of inflammation-related diseases .
    NF-κB degrader 1
  • HY-134476
    NF-κΒ activator 1
    5+ Cited Publications

    		 NF-κB Inflammation/Immunology
    NF-κΒ activator 1 (compound 32) is a potent NF-κΒ activator with an EC50 of 0.9 μM. NF-κΒ activator 1 induces superoxide dismutase (SOD)2 mRNA expression .
    NF-κΒ activator 1
  • HY-146058
    NF-κB/PON1-IN-1

    		NF-κB Reactive Oxygen Species (ROS) Cancer
    NF-κB/PON1-IN-1 (Compound 16) is a NF-κB/PON1 pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC50 = 45.76 µM) and hepatoprotective activities .
    NF-κB/PON1-IN-1
  • HY-112461A
    NF449 octasodium
    2 Publications Verification

    		 P2X Receptor Cardiovascular Disease
    NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a Gsα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449 octasodium
  • HY-108672
    NF157

    		P2Y Receptor Inflammation/Immunology
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .
    NF157
  • HY-173488
    NF-κB/HIF-1α-IN-1

    		NF-κB HIF/HIF Prolyl-Hydroxylase Keap1-Nrf2 Cancer
    NF-κB/HIF-1α-IN-1 (compound 9c) is a potent blocker of the NF-κB activation pathway and demonstrates selective anti-fibrotic activity. NF-κB/HIF-1α-IN-1 shows no significant cytotoxicity in NCI tumor cell lines. In rat models. NF-κB/HIF-1α-IN-1 has been shown to effectively ameliorate liver fibrosis by inhibiting the expression levels of NF-κB and HIF-1α, while simultaneously inducing the activation of Nrf2 .
    NF-κB/HIF-1α-IN-1
  • HY-RS23326
    Nf2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nf2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nf2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nf2 Rat Pre-designed siRNA Set A
    Nf2 Rat Pre-designed siRNA Set A
  • HY-RS17398
    Nf1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nf1 Mouse Pre-designed siRNA Set A
    Nf1 Mouse Pre-designed siRNA Set A
  • HY-RS09233
    NF1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NF1 Human Pre-designed siRNA Set A contains three designed siRNAs for NF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NF1 Human Pre-designed siRNA Set A
    NF1 Human Pre-designed siRNA Set A
  • HY-RS23853
    Nf1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nf1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nf1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nf1 Rat Pre-designed siRNA Set A
    Nf1 Rat Pre-designed siRNA Set A
  • HY-RS09234
    NF2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NF2 Human Pre-designed siRNA Set A contains three designed siRNAs for NF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NF2 Human Pre-designed siRNA Set A
    NF2 Human Pre-designed siRNA Set A
  • HY-RS16884
    Nf2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nf2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nf2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nf2 Mouse Pre-designed siRNA Set A
    Nf2 Mouse Pre-designed siRNA Set A
  • HY-A0059R
    Nifuratel (Standard)

    NF 113 (Standard); SAP 113 (Standard); Methylmercadone (Standard)

    		 Reference Standards Bacterial Parasite Antibiotic Infection
    Nifuratel (Standard) is the analytical standard of Nifuratel. This product is intended for research and analytical applications. Nifuratel (NF 113, SAP 113) is a broad-spectrum antibiotic with activity against bacteria, fungi and trichomonas.
    Nifuratel (Standard)
  • HY-108676
    NF023 hexasodium
    1 Publications Verification

    		 P2X Receptor Neurological Disease
    NF023 hexasodium is a selective and competitive P2X1 receptor antagonist, with IC50 values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X1, P2X3, P2X2, and P2X4-mediated responses respectively .
    NF023 hexasodium
  • HY-A0059
    Nifuratel
    3 Publications Verification

    NF 113; SAP 113; Methylmercadone

    		 Bacterial Parasite Antibiotic Fungal Apoptosis STAT Interleukin Related TNF Receptor Infection Inflammation/Immunology Cancer
    Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases .
    Nifuratel
  • HY-RS26569
    Nfasc Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Nfasc Rat Pre-designed siRNA Set A contains three designed siRNAs for Nfasc gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Nfasc Rat Pre-designed siRNA Set A
    Nfasc Rat Pre-designed siRNA Set A
  • HY-RS09236
    NFASC Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NFASC Human Pre-designed siRNA Set A contains three designed siRNAs for NFASC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NFASC Human Pre-designed siRNA Set A
    NFASC Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: